Compare · KRMD vs WST
KRMD vs WST
Side-by-side comparison of KORU Medical Systems Inc. (KRMD) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KRMD and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.59B, about 123.3x KRMD ($183.3M).
- Over the past year, KRMD is up 31.1% and WST is up 49.5% - WST leads by 18.4 points.
- KRMD has been more active in the news (10 items in the past 4 weeks vs 5 for WST).
- WST has more recent analyst coverage (17 ratings vs 6 for KRMD).
- Company
- KORU Medical Systems Inc.
- West Pharmaceutical Services Inc.
- Price
- $3.98-0.50%
- $334.67+4.58%
- Market cap
- $183.3M
- $22.59B
- 1M return
- -5.91%
- +2.67%
- 1Y return
- +31.14%
- +49.51%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 10
- 5
- Recent ratings
- 6
- 17
KORU Medical Systems Inc.
Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest KRMD
- KORU Medical Systems Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Technology Officer Schiller Eric bought $19,562 worth of shares (5,000 units at $3.91) (SEC Form 4)
- Amendment: Chief Executive Officer Tharby Linda M bought $4,669 worth of shares (1,191 units at $3.92), increasing direct ownership by 0.19% to 620,622 units (SEC Form 4)
- Chief Executive Officer Tharby Linda M bought $1,418,481 worth of shares (1,191 units at $1,191.00), increasing direct ownership by 0.19% to 620,622 units (SEC Form 4)
- Chief Executive Officer Tharby Linda M converted options into 13,977 shares and covered exercise/tax liability with 7,326 shares, increasing direct ownership by 1% to 619,431 units (SEC Form 4) (for withholding tax)
- Chief Operating Officer Pazdan Christopher converted options into 5,327 shares and covered exercise/tax liability with 1,470 shares, increasing direct ownership by 1% to 308,988 units (SEC Form 4) to cover withholding tax
- Chief Operating Officer Pazdan Christopher bought $19,400 worth of shares (5,000 units at $3.88), increasing direct ownership by 2% to 305,131 units (SEC Form 4)
- Chief Financial Officer Adams Thomas Edward converted options into 8,193 shares and covered exercise/tax liability with 2,900 shares, increasing direct ownership by 2% to 313,440 units (SEC Form 4) to cover taxes
- Chief Financial Officer Adams Thomas Edward bought $21,248 worth of shares (5,500 units at $3.86), increasing direct ownership by 2% to 308,147 units (SEC Form 4)
- KORU Medical Systems Presents Real World Data on the Benefits of the FreedomEDGE Syringe Infusion System in Infusion Clinics at the 51st Annual Oncology Nursing Society Congress
Latest WST
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)